Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

<h3>Background</h3><p dir="ltr">There is limited evidence in the literature on the long-term effectiveness and cost-effectiveness of treatments for Acute Severe Ulcerative Colitis (ASUC). The study aimed to perform decision analytic model-based long-term cost-utility anal...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Mohammed Fasihul Alam (6832217) (author)
مؤلفون آخرون:	Mirella Longo (6833627) (author), David Cohen (133780) (author), Sam Groves (5234345) (author), Laith Alrubaiy (15267632) (author), Hayley A. Hutchings (14085594) (author), Alan Watkins (432126) (author), Shaji Sebastain (15267635) (author), John G. Williams (111321) (author)
منشور في:	2023
الموضوعات:	Human society Policy and administration Ulcerative colitis Infiximab Ciclosporin Cost-efectiveness Decision tree Markov model
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial

مواد مشابهة